Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | LITESPARK-004: ESA use in VHL disease-associated RCC

Benjamin Maughan, MD, PharmD, University of Utah, Salt Lake City, UT, comments on findings from a post hoc analysis of the Phase II LITESPARK-004 study (NCT03401788). Belzutifan, a HIF-2α inhibitor, demonstrated antitumor activity in Von Hippel-Lindau syndrome (VHL) disease-associated renal cell carcinoma (RCC). The study explored the impact of erythropoietin-stimulating agent (ESA) use on belzutifan’s efficacy and results indicated that ESA administration did not compromise overall drug exposure or treatment efficacy. The objective response rate (ORR) and duration of response (DOR) were comparable between patients receiving ESA and those who did not across various neoplasms associated with VHL disease. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.